Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. Vijay Maruti Patil , Vanita Noronha , Nandini Menon , Ajay Singh , Sarbani Ghosh-Laskar , Ashwini Budrukkar , Atanu Bhattacharjee , Monali Swain , Vijayalakshmi Mathrudev , Kavita Nawale , Arun Balaji , Zoya Peelay , Mitali Alone , Shruti Pathak , Abhishek Mahajan , Suman Kumar , Nilendu Purandare , Archi Agarwal , Ameya Puranik , Shantanu Pendse , Monica Reddy Yallala , Harsh Sahu , Venkatesh Kapu , Sayak Dey , Jatin Choudhary , Madala Ravi Krishna , Alok Shetty , Naveen Karuvandan , Rahul Ravind , Rahul Rai , Kunal Jobanputra , Pankaj Chaturvedi , Prathamesh S Pai , Devendra Chaukar , Sudhir Nair , Shivakumar Thiagarajan , Kumar Prabhash JOURNAL OF CLINICAL ONCOLOGY（2023）
摘要
The addition of docetaxel to radiation improved DFS and OS in cisplatin-ineligible patients with LAHNSCC.[Media: see text].
更多 查看译文
关键词
neck cancer, radiosensitizer, docetaxel, phase iii randomized trial, cisplatin-based
AI 理解论文
溯源树
样例
